RT Journal Article
SR Electronic
T1 SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20183947
DO 10.1101/2020.09.03.20183947
A1 Graham J. Britton
A1 Alice Chen-Liaw
A1 Francesca Cossarini
A1 Alexandra E. Livanos
A1 Matthew P. Spindler
A1 Tamar Plitt
A1 Joseph Eggers
A1 Ilaria Mogno
A1 Ana S. Gonzalez-Reiche
A1 Sophia Siu
A1 Michael Tankelevich
A1 Lauren Tal Grinspan
A1 Rebekah E. Dixon
A1 Divya Jha
A1 Gustavo Martinez-Delgado
A1 Fatima Amanat
A1 Daisy A. Hoagland
A1 Benjamin R. tenOever
A1 Marla C. Dubinsky
A1 Miriam Merad
A1 Harm van Bakel
A1 Florian Krammer
A1 Gerold Bongers
A1 Saurabh Mehandru
A1 Jeremiah J. Faith
YR 2020
UL http://medrxiv.org/content/early/2020/09/05/2020.09.03.20183947.abstract
AB Background and aims Immune dysregulation caused by SARS-CoV-2 infection is thought to play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including intestinal epithelial cells. We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19.Methods We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody responses in stool and serum samples from a prospectively enrolled cohort of 44 hospitalized COVID-19 patients.Results SARS-CoV-2 RNA was detected in stool of 41% of patients and was found more frequently in patients with diarrhea than those without (16[44%] vs 5[19%], p=0.06). Patients who survived had lower median viral genome copies than those who did not (p=0.021). Compared to uninfected controls, COVID-19 patients had higher median fecal levels of IL-8 (166.5 vs 286.5 pg/mg; p=0.05) and lower levels of fecal IL-10 (678 vs 194 pg/mg; p<0.001) compared to uninfected controls. Stool IL-23 was higher in patients with more severe COVID-19 disease (223.8 vs 86.6 pg/mg; p=0.03) and we find evidence of intestinal virus-specific IgA responses, which was associated with more severe disease. Fecal cytokines and calprotectin levels were not correlated with gastrointestinal symptoms or with the level of virus detected.Conclusions Although SARS-CoV-2 RNA was detectable in the stools of COVID-19 patients and select individuals had evidence for a specific mucosal IgA response, intestinal inflammation was limited, even in patients presenting with gastrointestinal symptoms.Competing Interest StatementM.C.D is a consultant for Abbvie, Arena, BMS, Boehringer Ingelheim, Genentech, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target RWE and UCB, has received research support from Janssen, Pfizer, Prometheus Biosciences and Abbvie and is co-founder of Cornerstones Health, Mitest Health, Trellus Health, M.M. is a consultant for Takeda, Genentech, Regeneron, Compugen, Myeloid Therapeutics. F.K. declares that The Icahn School of Medicine at Mount Sinai has filed patent applications regarding SARS-CoV-2 serology assays and has licensed reagents to several commercial entities. J.J.F. serves on the scientific advisor board of Vedanta Biosciences. The remaining authors declare no conflicts of interest.Funding StatementThis work was supported by grants from the NIH (NIGMS GM108505, NIDDK DK112978, and NIDDK DK124133 to J.J.F and NIDDK DK123749 to S.M. and J.J.F.). G.J.B. is supported by a Research Fellowship Award from the Crohn's and Colitis Foundation of America. M.P.S. is supported by NIH T32 5T32AI007605. H.v.B. and A.S.G.-R were supported in part by the Centers of Excellence for Influenza Research and Surveillance contract HHSN272201400008C and A.S.G-R. was further supported in part by a Robin Chemers Neustein Postdoctoral Fellowship Award. Work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, and the generous support of the JPB foundation, the Open Philanthropy Project (2020-215611) and other philanthropic donations. Computational resources used in this research were further supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under awards S10OD018522 and S10OD026880. The funders had no role in the study design or manuscript preparationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the institutional review board at Icahn School of Medicine at Mount Sinai (Protocol #: HS# 16-00512/ GCO# 16-0583 and HS# 11-01669).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes16S amplicon and metagenomic sequencing data has been deposited to NCBI under Bioproject PRJNA660883. Viral genomes have been deposited to GISAID and Genbank. De-identified raw source data used to generate all figures is provided in the supplemental information.